ArticleBMC ophthalmology2026
Systemic inflammation in optic neuropathies: comparative insights from hematological and composite indices.
Article in BMC ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo compare complete blood count (CBC)-derived inflammatory indices among patients with multiple sclerosis-associated optic neuritis (MS-ON), non-arteritic anterior ischemic optic neuropathy (NAION), idiopathic intracranial hypertension-related optic neuropathy (IIH-ON), and healthy controls, while accounting for demographic confounding.
methodsThis retrospective study included 135 participants: 36 patients with MS-ON, 29 with NAION, 34 with IIH-ON, and 36 healthy controls. Six composite inflammatory indices, neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), systemic immune-inflammation index (SII), systemic inflammation response index (SIRI), pan-immune-inflammation value (PIV), and hemoglobin-albumin-lymphocyte-platelet (HALP) score, were calculated from routine laboratory measurements obtained at diagnosis before treatment. Log-transformed indices were compared using analysis of covariance adjusted for age and sex. False discovery rate correction was applied across the six indices. Receiver operating characteristic (ROC) analysis was performed for indices showing significant adjusted group effects.
resultsSignificant differences in age and sex distribution were observed among the groups. After adjustment for age and sex, overall group effects remained for NLR (p = 0.008) and SIRI (p = 0.033), although only NLR remained significant after false discovery rate correction (q = 0.047). Bonferroni-adjusted pairwise comparisons demonstrated higher NLR in MS-ON than in healthy controls (adjusted geometric means 2.83 vs. 1.80, p = 0.005). NLR discriminated MS-ON from controls with an area under the ROC curve (AUC) of 0.681 (95% CI, 0.554-0.807), while SIRI showed a comparable AUC of 0.661 (95% CI, 0.535-0.787). Among conventional hematological parameters, red cell distribution width remained elevated in IIH-ON, whereas serum albumin remained lower in MS-ON and IIH-ON after adjustment.
conclusionsIn the primary analysis, NLR was the only index that retained significance after adjustment for age, sex, and multiple testing, with higher values in MS-ON than in healthy controls. The sensitivity of several other indices to robust inference and the modest ROC performance warrant cautious interpretation and prospective validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.